NO20026012L - HMG-CoA-reduktase-inhibitorer og fremgangsmåte - Google Patents

HMG-CoA-reduktase-inhibitorer og fremgangsmåte

Info

Publication number
NO20026012L
NO20026012L NO20026012A NO20026012A NO20026012L NO 20026012 L NO20026012 L NO 20026012L NO 20026012 A NO20026012 A NO 20026012A NO 20026012 A NO20026012 A NO 20026012A NO 20026012 L NO20026012 L NO 20026012L
Authority
NO
Norway
Prior art keywords
hmg
coa reductase
reductase inhibitors
inhibitors
coa
Prior art date
Application number
NO20026012A
Other languages
English (en)
Norwegian (no)
Other versions
NO20026012D0 (no
Inventor
Jeffrey A Robl
Bang-Chi Chen
Chong-Qing Sun
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20026012D0 publication Critical patent/NO20026012D0/no
Publication of NO20026012L publication Critical patent/NO20026012L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
NO20026012A 2000-06-15 2002-12-13 HMG-CoA-reduktase-inhibitorer og fremgangsmåte NO20026012L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21159500P 2000-06-15 2000-06-15
PCT/US2001/018864 WO2001096347A1 (en) 2000-06-15 2001-06-12 HMG-CoA REDUCTASE INHIBITORS AND METHOD

Publications (2)

Publication Number Publication Date
NO20026012D0 NO20026012D0 (no) 2002-12-13
NO20026012L true NO20026012L (no) 2003-02-03

Family

ID=22787569

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026012A NO20026012L (no) 2000-06-15 2002-12-13 HMG-CoA-reduktase-inhibitorer og fremgangsmåte

Country Status (22)

Country Link
US (1) US20020013334A1 (cs)
EP (1) EP1294728A1 (cs)
JP (1) JP2004503557A (cs)
KR (1) KR20030036225A (cs)
CN (1) CN1436192A (cs)
AR (1) AR030700A1 (cs)
AU (1) AU2001266858A1 (cs)
BR (1) BR0111599A (cs)
CA (1) CA2412632A1 (cs)
CZ (1) CZ20023930A3 (cs)
EC (1) ECSP024384A (cs)
HU (1) HUP0302937A2 (cs)
IL (1) IL152490A0 (cs)
MX (1) MXPA02012252A (cs)
NO (1) NO20026012L (cs)
NZ (1) NZ523627A (cs)
PE (1) PE20020254A1 (cs)
PL (1) PL359820A1 (cs)
RU (1) RU2003101064A (cs)
UY (1) UY26777A1 (cs)
WO (1) WO2001096347A1 (cs)
ZA (1) ZA200210103B (cs)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7792601A (en) * 2000-07-20 2002-02-05 Bristol Myers Squibb Co Regulators of ppardelta(beta) and their use in the treatment of obesity and insulin resistance
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1695716A2 (en) * 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
DE60220269T2 (de) * 2001-01-26 2008-01-17 Schering Corp. Kombinationen eines hemmers der sterolabsorption und eines kardiovaskulären wirkstoffes zur behandlung von kardiovaskulären indikationen
JP2004517916A (ja) * 2001-01-26 2004-06-17 シェーリング　コーポレイション ニコチン酸およびその誘導体ならびにステロール吸収阻害剤の併用、および血管適応症の治療
ES2274013T3 (es) 2001-01-26 2007-05-16 Schering Corporation Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
EP1864680A3 (en) * 2001-01-26 2012-03-28 Schering Corporation Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AR032403A1 (es) * 2001-01-26 2003-11-05 Schering Corp Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
CZ20033329A3 (cs) * 2001-06-06 2004-11-10 Bristol-Myers Squibb Company Způsob přípravy chirálních sulfondiolů a dihydroxykyselin inhibitorů HMG CoA reduktázy
GB0119460D0 (en) * 2001-08-09 2001-10-03 Ark Therapeutics Ltd The use of inhibitors of the renin-angiotensin system
BR0212512A (pt) 2001-09-14 2004-10-26 Tularik Inc Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
BR0215258A (pt) 2001-12-21 2004-12-07 Pharmacia Corp Moduladores de receptor x de fìgado de tioéter aromático
US20060058369A1 (en) * 2002-02-19 2006-03-16 Vanderbilt University Therapeutic methods employing PAI-1 inhibitors and transgenic non-human animal for screening candidate PAI-1 inhibitors
EP1487458B1 (en) 2002-02-28 2011-11-16 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
JP2006509716A (ja) * 2002-03-12 2006-03-23 マイクロドース・テクノロジーズ・インコーポレーテッド 吸入で同時投与した薬剤を特定部位へ届ける方法
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
BR0311282A (pt) * 2002-05-24 2005-04-19 Pharmacia Corp Moduladores sulfona de receptor-x do fìgado
MXPA04011691A (es) * 2002-05-24 2005-09-12 Pharmacia Corp Moduladores del receptor x anilino hepaticos.
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
ATE485818T1 (de) * 2002-07-30 2010-11-15 Karykion Inc Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
CA2494061C (en) * 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
MXPA05002914A (es) * 2002-09-17 2005-05-27 Pharmacia Corp Moduladores de los receptores x hepaticos aromaticos.
US7629347B2 (en) * 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
GB0228894D0 (en) * 2002-12-11 2003-01-15 Avecia Ltd Process
DE502004003880D1 (de) * 2003-01-16 2007-07-05 Boehringer Ingelheim Pharma Pharmazeutische kombination zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
WO2004081003A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US7601756B2 (en) * 2003-06-06 2009-10-13 Snowden Pharmaceuticals, Llc Method of treatment for irritable bowel syndrome
CN1852748A (zh) * 2003-07-23 2006-10-25 埃克塞里艾克西斯公司 用作药物的氮杂䓬衍生物
US20080058292A1 (en) * 2003-10-29 2008-03-06 Raif Tawakol Method for increasing HDL and HDL-2b levels
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20060058283A1 (en) * 2004-09-15 2006-03-16 Zymes, Inc. Compositions comprising ubiquinones
US20070185065A1 (en) * 2006-02-03 2007-08-09 Vikramjit Chhokar Combination therapy for coronary artery disease
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
WO2008059519A2 (en) * 2006-09-25 2008-05-22 Glenmark Pharmaceuticals Limited A process for the preparation of intermediates of rosuvastatin
EP2121681B1 (en) 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
KR100900044B1 (ko) 2007-07-05 2009-06-01 한국식품연구원 3-하이드록시-3-메틸글루타릴 보조효소 ａ 환원효소 저해용펩타이드 및 이를 함유하는 고콜레스테롤로 인한 심장질환 및 심혈관계 질환 치료제
WO2009079765A1 (en) * 2007-12-21 2009-07-02 Cascade Therapeutics Inc. Compounds with activity at the 5-ht2c receptor
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CN102698276B (zh) * 2008-01-03 2014-12-10 艾克斯-马赛大学 抗hiv治疗期间使用的组合物和方法
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CA2764153C (en) 2009-06-02 2021-07-27 The Board Of Regents Of The University Of Texas System Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
ES2702753T3 (es) * 2010-01-05 2019-03-05 Microdose Therapeutx Inc Dispositivo de inhalación
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
EP2588474A4 (en) * 2010-07-01 2014-07-23 Yuhan Corp PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATE PRODUCTS THEREOF
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103360384A (zh) * 2013-07-30 2013-10-23 浙江京新药业股份有限公司 HMG-CoA还原酶抑制剂关键中间体的合成方法
CN106822903B (zh) * 2017-02-13 2019-07-23 牡丹江医学院 用于治疗心衰的药物组合物及其应用
CN107164544A (zh) * 2017-07-18 2017-09-15 孙葆青 通过高通量测序快速检测阿托伐他汀钙的敏感性的方法
WO2019208740A1 (ja) 2018-04-27 2019-10-31 三ツ星ベルト株式会社 Ｖリブドベルト及びその用途
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用
CN114213350B (zh) * 2021-12-29 2024-03-19 江苏福瑞康泰药业有限公司 一种他汀类药物中间体的制备方法
CN114437052B (zh) * 2021-12-31 2024-03-29 江苏阿尔法集团福瑞药业(宿迁)有限公司 一种利用连续流微通道反应器合成他汀类药物中间体的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) * 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
ZA911046B (en) * 1990-02-26 1992-10-28 Squibb & Sons Inc Quinoline and pyridine anchors for hmg-coa reductase inhibitors
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine

Also Published As

Publication number Publication date
HUP0302937A2 (hu) 2003-12-29
RU2003101064A (ru) 2004-08-10
UY26777A1 (es) 2002-01-31
US20020013334A1 (en) 2002-01-31
NO20026012D0 (no) 2002-12-13
BR0111599A (pt) 2004-10-13
MXPA02012252A (es) 2003-06-06
KR20030036225A (ko) 2003-05-09
CZ20023930A3 (cs) 2003-03-12
CA2412632A1 (en) 2001-12-20
IL152490A0 (en) 2003-05-29
JP2004503557A (ja) 2004-02-05
PL359820A1 (en) 2004-09-06
AU2001266858A1 (en) 2001-12-24
AR030700A1 (es) 2003-09-03
NZ523627A (en) 2004-10-29
EP1294728A1 (en) 2003-03-26
ZA200210103B (en) 2004-03-12
ECSP024384A (es) 2003-03-31
CN1436192A (zh) 2003-08-13
WO2001096347A1 (en) 2001-12-20
PE20020254A1 (es) 2002-04-03

Similar Documents

Publication Publication Date Title
NO20026012D0 (no) HMG-CoA-reduktase-inhibitorer og metode
NO20026011D0 (no) HMG-CoA-reduktase-inhibitorer og fremgangsmåte
NO20014823L (no) Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
EP1684754A4 (en) HMG COA REDUCTASE INHIBITORS AND METHOD
NO20032668L (no) Gyraseinhibitorer og anvendelser derav
NO20044915L (no) C-aryl-glukosid SGLT2 inhibitorer og metode
NO20024295D0 (no) Cyclopropyl-kondenserte pyrrolidin-baserte inhibitorer av dipeptidyl peptidase IV og fremgangsmåte
DE60211317D1 (de) Rho-kinase inhibitoren
DE60218138D1 (de) Rho-kinase inhibitoren
DK1223918T3 (da) Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor
NO20025416L (no) System og fremgangsmåte ved ekspanderbar komplettering
ATE269701T1 (de) Gyrase-inhibitoren und ihre verwendung
NO20052779D0 (no) Doseringsformer omfattende en CETP-inhibitor og en HMG-CoA-reduktaseinhibitor.
NO20040865L (no) Friksjon reduserende sammensetning og metode
NO20026054D0 (no) Akustisk loggeapparat og fremgangsmåte
IS6691A (is) Aðferð og algoritmi til að greina mRNA tjáningu
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
ATE502118T1 (de) Amplifizierungsverfahren
FI20000715A0 (fi) Ryhmätyömenetelmä ja -järjestelmä
DE60231591D1 (de) Aufzeichnungsvorrichtung und -verfahren
DE60135813D1 (de) CDMA Empfangsgerät und -verfahren
GB0113040D0 (en) Inhibitor function check method and apparatus
AU5258701A (en) Method of searching for arteriosclerosis inhibitors and shrinkers
HK1051044A (en) Hmg-coa reductase inhibitors and method

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application